Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | MTOR | P42345 | 2/20 | 0.81 |
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.81 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.81 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL21423095 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL30115 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL12031031 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL14565251 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL14580391 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL30117 | 1.00 | LMNA (0.81) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL8680244 | 0.96 | LMNA (0.83) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL8680234 | 0.96 | LMNA (0.83) | LMNAMTORTHRBMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL21465076 | 0.95 | LMNA (0.74) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0016005-B1 | 2'-SUBSTITUTED BETA-ARABINOFURANOSYL NUCLEOSIDES AND NUCLEOTIDES, PREPARATION AND USE THEREOF | Research Corporation (US) | 1984-07-25 | — | — | EP | claimed |
| US-4230698-A | ANTITUMOR AGENTS, VIRICIDES, AND MICROBIOCIDES | RESEARCH CORPORATION (US) | 1980-10-28 | — | — | US | claimed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2015058069-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015051214-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015048744-A2 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2009136158-A1 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHEIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE | CYCLACEL LIMITED (GB) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009136162-A1 | INTERMEDIATE AND PROCESSES INVOLVED IN THE PREPARATION OF 2 ' -CYANO-2 ' -DE0XY-N4-PALMIT0YL-1-BETA-ARABIN0FURAN0SYLCYTOSINE | CYCLACEL LIMITED (GB) | 2009-11-12 | — | — | WO | disclosed |
| EP-0016005-B1 | 2'-SUBSTITUTED BETA-ARABINOFURANOSYL NUCLEOSIDES AND NUCLEOTIDES, PREPARATION AND USE THEREOF | Research Corporation (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4321366-A | Process of preparing 2-azido-2-deoxyarabinofuranosyl halides | RESEARCH CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
| US-4230698-A | ANTITUMOR AGENTS, VIRICIDES, AND MICROBIOCIDES | RESEARCH CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | LMNA 1728/4885MTOR 3465/4885THRB 4801/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | LMNA 4705/4885MTOR 3122/4885THRB 4013/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | LMNA 2139/4885MTOR 3506/4885THRB 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.